From: Targeted delivery of immuno-RNase may improve cancer therapy
 | Original length (μmol/L) | Length at 48 h (μmol/L) | Healing rate (%) | ||||
---|---|---|---|---|---|---|---|
Blank control | 829 | 914 | 784 | 0 | 0 | 0 | 100 |
 0.05 | 830 | 702 | 577 | 71 | 65 | 29 | 92.39 ± 2.27 |
 0.10 | 714 | 815 | 572 | 94 | 108 | 78 | 86.65 ± 0.25# |
 0.20 | 928 | 691 | 825 | 325 | 221 | 289 | 65.99 ± 1.76# |
 0.40 | 812 | 658 | 502 | 490 | 422 | 316 | 37.52 ± 1.94# |
 0.80 | 901 | 847 | 956 | 783 | 749 | 810 | 13.31 ± 1.86# |
 1.60 | 793 | 933 | 960 | 740 | 892 | 923 | 4.98 ± 1.50# |
 3.20 | 947 | 809 | 716 | 902 | 758 | 679 | 5.41 ± 0.80# |
Positive control | 812 | 762 | 892 | 352 | 315 | 411 | 56.41 ± 2.38# |